<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37652022</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>The penetrance of rare variants in cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for secondary findings.</ArticleTitle><Pagination><StartPage>1482</StartPage><EndPage>1495</EndPage><MedlinePgn>1482-1495</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2023.08.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(23)00279-3</ELocationID><Abstract><AbstractText>Understanding the penetrance of pathogenic variants identified as secondary findings (SFs) is of paramount importance with the growing availability of genetic testing. We estimated penetrance through large-scale analyses of individuals referred for diagnostic sequencing for hypertrophic cardiomyopathy (HCM; 10,400 affected individuals, 1,332 variants) and dilated cardiomyopathy (DCM; 2,564 affected individuals, 663 variants), using a cross-sectional approach comparing allele frequencies against reference populations (293,226 participants from UK Biobank and gnomAD). We generated updated prevalence estimates for HCM (1:543) and DCM (1:220). In aggregate, the penetrance by late adulthood of rare, pathogenic variants (23% for HCM, 35% for DCM) and likely pathogenic variants (7% for HCM, 10% for DCM) was substantial for dominant cardiomyopathy (CM). Penetrance was significantly higher for variant subgroups annotated as loss of function or ultra-rare and for males compared to females for variants in HCM-associated genes. We estimated variant-specific penetrance for 316 recurrent variants most likely to be identified as SFs (found in 51% of HCM- and 17% of DCM-affected individuals). 49 variants were observed at least ten times (14% of affected individuals) in HCM-associated genes. Median penetrance was 14.6% (&#xb1;14.4% SD). We explore estimates of penetrance by age, sex, and ancestry and simulate the impact of including future cohorts. This dataset reports penetrance of individual variants at scale and will inform the management of individuals undergoing genetic screening for SFs. While most variants had low penetrance and the costs and harms of screening are unclear, some individuals with highly penetrant variants may benefit from SFs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGurk</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; MRC London Institute of Medical Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaolei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theotokis</LastName><ForeName>Pantazis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; MRC London Institute of Medical Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomson</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and the Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harper</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and the Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchan</LastName><ForeName>Rachel J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; MRC London Institute of Medical Sciences, Imperial College London, London, UK; Royal Brompton &amp; Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazaika</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ormondroyd</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and the Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>William T</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, Belfast City Hospital, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macaya</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>GeneDx LLC, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pua</LastName><ForeName>Chee Jian</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>National Heart Research Institute Singapore and Duke-National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funke</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Centre for Population Genomics, Garvan Institute of Medical Research and UNSW, Sydney, NSW, Australia; Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Sanjay K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton &amp; Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>MRC London Institute of Medical Sciences, Imperial College London, London, UK; National Heart Research Institute Singapore and Duke-National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allouba</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; Aswan Heart Centre, Aswan, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguib</LastName><ForeName>Yasmine</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; Aswan Heart Centre, Aswan, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yacoub</LastName><ForeName>Magdi H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton &amp; Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK; Aswan Heart Centre, Aswan, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Regan</LastName><ForeName>Declan P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>MRC London Institute of Medical Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Paul J R</ForeName><Initials>PJR</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; MRC London Institute of Medical Sciences, Imperial College London, London, UK; Royal Brompton &amp; Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Hugh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Radcliffe Department of Medicine and the Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottolo</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, University of Cambridge, Cambridge, UK; The Alan Turing Institute, London, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ware</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK; MRC London Institute of Medical Sciences, Imperial College London, London, UK; Royal Brompton &amp; Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK. Electronic address: j.ware@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U120085815</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RG/18/9/33887</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC-A658-5TY00</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BBC/F/21/220106</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>FS/IPBSRF/22/27059</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1605/13</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RG/19/6/34387</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RE/18/4/34215</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200990/A/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_1102/20</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>107469/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019683" MajorTopicYN="N">Penetrance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009202" MajorTopicYN="Y">Cardiomyopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002312" MajorTopicYN="Y">Cardiomyopathy, Hypertrophic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002311" MajorTopicYN="Y">Cardiomyopathy, Dilated</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">penetrance</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">secondary findings</Keyword></KeywordList><CoiStatement>Declaration of interests J.S.W. has consulted for MyoKardia, Inc., Foresite Labs, and Pfizer. A.H. now works for AstraZeneca, UK. D.P.O. has consulted for Bayer. L.B. has consulted for Roche. D.G.M. is a paid advisor to GlaxoSmithKline, Insitro, Variant Bio, and Overtone Therapeutics and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Merck, Pfizer, and Sanofi-Genzyme; none of these activities are directly related to the work presented here. E.M. is the owner of Mazalytics LLC, Boston, Massachusetts, USA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37652022</ArticleId><ArticleId IdType="pmc">PMC10502871</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2023.08.003</ArticleId><ArticleId IdType="pii">S0002-9297(23)00279-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blout Zawatsky C.L., Bick D., Bier L., Funke B., Lebo M., Lewis K.L., Orlova E., Qian E., Ryan L., Schwartz M.L.B., Soper E.R. Elective genomic testing: Practice resource of the National Society of Genetic Counselors. J.&#xa0;Genet. Couns. 2023;32:281&#x2013;299. doi: 10.1002/jgc4.1654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgc4.1654</ArticleId><ArticleId IdType="pubmed">36597794</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller D.T., Lee K., Abul-Husn N.S., Amendola L.M., Brothers K., Chung W.K., Gollob M.H., Gordon A.S., Harrison S.M., Hershberger R.E., et al. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG) Genet. Med. 2022;24:1407&#x2013;1414. doi: 10.1016/j.gim.2022.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gim.2022.04.006</ArticleId><ArticleId IdType="pubmed">35802134</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wert G., Dondorp W., Clarke A., Dequeker E.M.C., Cordier C., Deans Z., van El C.G., Fellmann F., Hastings R., Hentze S., et al. Opportunistic genomic screening. Recommendations of the European Society of Human Genetics. Eur. J. Hum. Genet. 2021;29:365&#x2013;377. doi: 10.1038/s41431-020-00758-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-020-00758-w</ArticleId><ArticleId IdType="pmc">PMC7940405</ArticleId><ArticleId IdType="pubmed">33223530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormondroyd E., Mackley M.P., Blair E., Craft J., Knight J.C., Taylor J.C., Taylor J., Watkins H. &#x201c;Not pathogenic until proven otherwise&#x201d;: Perspectives of UK clinical genomics professionals toward secondary findings in context of a Genomic Medicine Multidisciplinary Team and the 100,000 Genomes Project. Genet. Med. 2018;20:320&#x2013;328. doi: 10.1038/gim.2017.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2017.157</ArticleId><ArticleId IdType="pmc">PMC5880578</ArticleId><ArticleId IdType="pubmed">29261176</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk K.A., Zheng S.L., Henry A., Josephs K., Edwards M., de Marvao A., Whiffin N., Roberts A., Lumbers T.R., O&#x2019;Regan D.P., Ware J.S. Correspondence on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the&#xa0;American College of Medical Genetics and Genomics. Genet. Med. 2022;24:744&#x2013;746. doi: 10.1016/j.gim.2021.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gim.2021.10.020</ArticleId><ArticleId IdType="pubmed">34906520</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.M.G., Jungner G. World Health Organization; 1968. Principles and Practice of Screening for Disease: Public Health Papers No. 34.</Citation></Reference><Reference><Citation>Landstrom A.P., Chahal A.A., Ackerman M.J., Cresci S., Milewicz D.M., Morris A.A., Sarquella-Brugada G., Semsarian C., Shah S.H., Sturm A.C., American Heart Association Data Science and Precision Medicine Committee of the Council on Genomic and Precision Medicine and Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Peripheral Vascular Disease; and Stroke Council Interpreting Incidentally Identified Variants in Genes Associated With Heritable Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circ. Genom. Precis. Med. 2023;16 doi: 10.1161/HCG.0000000000000092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HCG.0000000000000092</ArticleId><ArticleId IdType="pubmed">36970980</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynn J., Martinez J., Bulafka J., Duong J., Zhang Y., Chiuzan C., Preti J., Cremona M.L., Jobanputra V., Fyer A.J., et al. Impact of Receiving Secondary Results from Genomic Research: A 12-Month Longitudinal Study. J.&#xa0;Genet. Couns. 2018;27:709&#x2013;722. doi: 10.1007/s10897-017-0172-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10897-017-0172-x</ArticleId><ArticleId IdType="pmc">PMC5945295</ArticleId><ArticleId IdType="pubmed">29168042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart M.R., Biesecker B.B., Blout C.L., Christensen K.D., Amendola L.M., Bergstrom K.L., Biswas S., Bowling K.M., Brothers K.B., Conlin L.K., et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genet. Med. 2019;21:1100&#x2013;1110. doi: 10.1038/s41436-018-0308-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-018-0308-x</ArticleId><ArticleId IdType="pmc">PMC6450774</ArticleId><ArticleId IdType="pubmed">30287922</ArticleId></ArticleIdList></Reference><Reference><Citation>Thauvin-Robinet C., Thevenon J., Nambot S., Delanne J., Kuentz P., Bruel A.-L., Chassagne A., Cretin E., Pelissier A., Peyron C., et al. Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. Eur. J. Hum. Genet. 2019;27:1197&#x2013;1214. doi: 10.1038/s41431-019-0384-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-019-0384-7</ArticleId><ArticleId IdType="pmc">PMC6777608</ArticleId><ArticleId IdType="pubmed">31019283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackley M.P., Fletcher B., Parker M., Watkins H., Ormondroyd E. Stakeholder views on secondary findings in whole-genome and whole-exome sequencing: A systematic review of quantitative and qualitative studies. Genet. Med. 2017;19:283&#x2013;293. doi: 10.1038/gim.2016.109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.109</ArticleId><ArticleId IdType="pmc">PMC5447864</ArticleId><ArticleId IdType="pubmed">27584911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormondroyd E., Harper A.R., Thomson K.L., Mackley M.P., Martin J., Penkett C.J., Salatino S., Stark H., Stephens J., Watkins H. Secondary findings in inherited heart conditions: a genotype-first feasibility study to assess phenotype, behavioural and psychosocial outcomes. Eur. J. Hum. Genet. 2020;28:1486&#x2013;1496. doi: 10.1038/s41431-020-0694-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-020-0694-9</ArticleId><ArticleId IdType="pmc">PMC7576165</ArticleId><ArticleId IdType="pubmed">32686758</ArticleId></ArticleIdList></Reference><Reference><Citation>de Marvao A., McGurk K.A., Zheng S.L., Thanaj M., Bai W., Duan J., Biffi C., Mazzarotto F., Statton B., Dawes T.J.W., et al. Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy. J.&#xa0;Am. Coll. Cardiol. 2021;78:1097&#x2013;1110. doi: 10.1016/j.jacc.2021.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.07.017</ArticleId><ArticleId IdType="pmc">PMC8434420</ArticleId><ArticleId IdType="pubmed">34503678</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirruccello J.P., Bick A., Wang M., Chaffin M., Friedman S., Yao J., Guo X., Venkatesh B.A., Taylor K.D., Post W.S., et al. Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nat. Commun. 2020;11:2254. doi: 10.1038/s41467-020-15823-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15823-7</ArticleId><ArticleId IdType="pmc">PMC7206184</ArticleId><ArticleId IdType="pubmed">32382064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirruccello J.P., Bick A., Chaffin M., Aragam K.G., Choi S.H., Lubitz S.A., Ho C.Y., Ng K., Philippakis A., Ellinor P.T., et al. Titin truncating variants in adults without known congestive heart failure. J.&#xa0;Am. Coll. Cardiol. 2020;75:1239&#x2013;1241. doi: 10.1016/j.jacc.2020.01.013.Titin.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.01.013.Titin</ArticleId><ArticleId IdType="pmc">PMC7433750</ArticleId><ArticleId IdType="pubmed">32164899</ArticleId></ArticleIdList></Reference><Reference><Citation>Castel S.E., Cervera A., Mohammadi P., Aguet F., Reverter F., Wolman A., Guigo R., Iossifov I., Vasileva A., Lappalainen T. Modified penetrance of coding variants by cis-regulatory variation contributes to disease risk. Nat. Genet. 2018;50:1327&#x2013;1334. doi: 10.1038/s41588-018-0192-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0192-y</ArticleId><ArticleId IdType="pmc">PMC6119105</ArticleId><ArticleId IdType="pubmed">30127527</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodrich J.K., Singer-Berk M., Son R., Sveden A., Wood J., England E., Cole J.B., Weisburd B., Watts N., Caulkins L., et al. Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. Nat. Commun. 2021;12:3505. doi: 10.1038/s41467-021-23556-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23556-4</ArticleId><ArticleId IdType="pmc">PMC8190084</ArticleId><ArticleId IdType="pubmed">34108472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingdom R., Wright C.F. Incomplete Penetrance and Variable Expressivity : From Clinical Studies to Population Cohorts. Front. Genet. 2022;13 doi: 10.3389/fgene.2022.920390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.920390</ArticleId><ArticleId IdType="pmc">PMC9380816</ArticleId><ArticleId IdType="pubmed">35983412</ArticleId></ArticleIdList></Reference><Reference><Citation>Glazier A.A., Thompson A., Day S.M. Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. Pflugers Arch. 2019;471:781&#x2013;793. doi: 10.1007/s00424-018-2226-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-018-2226-9</ArticleId><ArticleId IdType="pmc">PMC6476680</ArticleId><ArticleId IdType="pubmed">30456444</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts A.M., Ware J.S., Herman D.S., Schafer S., Baksi J., Bick A.G., Buchan R.J., Walsh R., John S., Wilkinson S., et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci. Transl. Med. 2015;7:270ra6. doi: 10.1126/scitranslmed.3010134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3010134</ArticleId><ArticleId IdType="pmc">PMC4560092</ArticleId><ArticleId IdType="pubmed">25589632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadros R., Francis C., Xu X., Vermeer A.M.C., Harper A.R., Huurman R., Kelu Bisabu K., Walsh R., Hoorntje E.T., te Rijdt W.P., et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat. Genet. 2021;53:128&#x2013;134. doi: 10.1038/s41588-020-00762-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00762-2</ArticleId><ArticleId IdType="pmc">PMC7611259</ArticleId><ArticleId IdType="pubmed">33495596</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper A.R., Goel A., Grace C., Thomson K.L., Petersen S.E., Xu X., Waring A., Ormondroyd E., Kramer C.M., Ho C.Y., et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 2021;53:135&#x2013;142. doi: 10.1038/s41588-020-00764-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-00764-0</ArticleId><ArticleId IdType="pmc">PMC8240954</ArticleId><ArticleId IdType="pubmed">33495597</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk K.A., Halliday B.P. Dilated cardiomyopathy&#xa0;&#x2013; details make the difference. Eur. J. Heart Fail. 2022;24:1197&#x2013;1199. doi: 10.1002/ejhf.2586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2586</ArticleId><ArticleId IdType="pubmed">35717623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gail M.H., Pee D., Benichou J., Carroll R. Designing studies to estimate the penetrance of an identified autosomal dominant mutation: Cohort, case-control, and genotyped-proband designs. Genet. Epidemiol. 1999;16:15&#x2013;39. doi: 10.1002/(SICI)1098-2272(1999)16:1&lt;15::AID-GEPI3&gt;3.0.CO;2-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-2272(1999)16:1&lt;15::AID-GEPI3&gt;3.0.CO;2-8</ArticleId><ArticleId IdType="pubmed">9915565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzini M., Norrish G., Field E., Ochoa J.P., Cicerchia M., Akhtar M.M., Syrris P., Lopes L.R., Kaski J.P., Elliott P.M. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J.&#xa0;Am. Coll. Cardiol. 2020;76:550&#x2013;559. doi: 10.1016/j.jacc.2020.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.06.011</ArticleId><ArticleId IdType="pmc">PMC7397507</ArticleId><ArticleId IdType="pubmed">32731933</ArticleId></ArticleIdList></Reference><Reference><Citation>Minikel E.V., Vallabh S.M., Lek M., Estrada K., Samocha K.E., Sathirapongsasuti J.F., McLean C.Y., Tung J.Y., Yu L.P.C., Gambetti P., et al. Quantifying prion disease penetrance using large population control cohorts. Sci. Transl. Med. 2016;8:322ra9. doi: 10.1126/scitranslmed.aad5169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad5169</ArticleId><ArticleId IdType="pmc">PMC4774245</ArticleId><ArticleId IdType="pubmed">26791950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde A.A.M., Semsarian C., M&#xe1;rquez M.F., Shamloo A.S., Ackerman M.J., Ashley E.A., Sternick E.B., Barajas-Martinez H., Behr E.R., Bezzina C.R., et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022;24:1307&#x2013;1367. doi: 10.1093/europace/euac030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac030</ArticleId><ArticleId IdType="pmc">PMC9435643</ArticleId><ArticleId IdType="pubmed">35373836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman M.J., Priori S.G., Willems S., Berul C., Brugada R., Calkins H., Camm A.J., Ellinor P.T., Gollob M., Hamilton R., et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Europace. 2011;13:1077&#x2013;1109. doi: 10.1093/europace/eur245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eur245</ArticleId><ArticleId IdType="pubmed">21810866</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C., Freeman C., Petkova D., Band G., Elliott L.T., Sharp K., Motyer A., Vukcevic D., Delaneau O., O&#x2019;Connell J., et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203&#x2013;209. doi: 10.1038/s41586-018-0579-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0579-z</ArticleId><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Szustakowski J.D., Balasubramanian S., Kvikstad E., Khalid S., Bronson P.G., Sasson A., Wong E., Liu D., Wade Davis J., Haefliger C., et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 2021;53:942&#x2013;948. doi: 10.1038/s41588-021-00885-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00885-0</ArticleId><ArticleId IdType="pubmed">34183854</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alf&#xf6;ldi J., Wang Q., Collins R.L., Laricchia K.M., Ganna A., Birnbaum D.P., et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;443. doi: 10.1038/s41586-020-2308-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W., Gil L., Hunt S.E., Riat H.S., Ritchie G.R.S., Thormann A., Flicek P., Cunningham F. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122. doi: 10.1186/s13059-016-0974-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-0974-4</ArticleId><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaganathan K., Kyriazopoulou Panagiotopoulou S., McRae J.F., Darbandi S.F., Knowles D., Li Y.I., Kosmicki J.A., Arbelaez J., Cui W., Schwartz G.B., et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019;176:535&#x2013;548.e24. doi: 10.1016/j.cell.2018.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.12.015</ArticleId><ArticleId IdType="pubmed">30661751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis N.M., Rothstein J.H., Pejaver V., Middha S., McDonnell S.K., Baheti S., Musolf A., Li Q., Holzinger E., Karyadi D., et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am. J. Hum. Genet. 2016;99:877&#x2013;885. doi: 10.1016/j.ajhg.2016.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.08.016</ArticleId><ArticleId IdType="pmc">PMC5065685</ArticleId><ArticleId IdType="pubmed">27666373</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum M.J., Lee J.M., Riley G.R., Jang W., Rubinstein W.S., Church D.M., Maglott D.R. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980&#x2013;D985. doi: 10.1093/nar/gkt1113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1113</ArticleId><ArticleId IdType="pmc">PMC3965032</ArticleId><ArticleId IdType="pubmed">24234437</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D., Maller J., Sklar P., de Bakker P.I.W., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007;81:559&#x2013;575. doi: 10.1086/519795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingles J., Goldstein J., Thaxton C., Caleshu C., Corty E.W., Crowley S.B., Dougherty K., Harrison S.M., McGlaughon J., Milko L.V., et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ. Genom. Precis. Med. 2019;12:e002460&#x2013;e002464. doi: 10.1161/CIRCGEN.119.002460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCGEN.119.002460</ArticleId><ArticleId IdType="pmc">PMC6410971</ArticleId><ArticleId IdType="pubmed">30681346</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan E., Peterson L., Ai T., Asatryan B., Bronicki L., Brown E., Celeghin R., Edwards M., Fan J., Ingles J., et al. Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation. 2021;144:7&#x2013;19. doi: 10.1161/CIRCULATIONAHA.120.053033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.053033</ArticleId><ArticleId IdType="pmc">PMC8247549</ArticleId><ArticleId IdType="pubmed">33947203</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs K.S., Roberts A.M., Theotokis P., Walsh R., Ostrowski P.J., Edwards M., Fleming A., Thaxton C., Roberts J.D., Care M., et al. Beyond gene-disease validity: capturing structured data on inheritance, allelic-requirement, disease-relevant variant classes, and disease mechanism for inherited cardiac conditions. medRxiv. 2023 doi: 10.1101/2023.04.03.23287612. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.03.23287612</ArticleId><ArticleId IdType="pmc">PMC10594882</ArticleId><ArticleId IdType="pubmed">37872640</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiffin N., Walsh R., Govind R., Edwards M., Ahmad M., Zhang X., Tayal U., Buchan R., Midwinter W., Wilk A.E., et al. CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation. Genet. Med. 2018;20:1246&#x2013;1254. doi: 10.1038/gim.2017.258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2017.258</ArticleId><ArticleId IdType="pmc">PMC6558251</ArticleId><ArticleId IdType="pubmed">29369293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y., Song L., Wang Z., Ma A., Liu T., Gu H., Lu S., Wu P., Zhang dagger Y., Shen dagger L., et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults. Am. J. Med. 2004;116:14&#x2013;18. doi: 10.1016/j.amjmed.2003.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2003.05.009</ArticleId><ArticleId IdType="pubmed">14706660</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron B.J., Spirito P., Roman M.J., Paranicas M., Okin P.M., Best L.G., Lee E.T., Devereux R.B. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study) Am. J. Cardiol. 2004;93:1510&#x2013;1514. doi: 10.1016/j.amjcard.2004.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2004.03.007</ArticleId><ArticleId IdType="pubmed">15194022</ArticleId></ArticleIdList></Reference><Reference><Citation>Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults. Circulation. 1995;92:785&#x2013;789. doi: 10.1161/01.cir.92.4.785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.92.4.785</ArticleId><ArticleId IdType="pubmed">7641357</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen S.E., Aung N., Sanghvi M.M., Zemrak F., Fung K., Paiva J.M., Francis J.M., Khanji M.Y., Lukaschuk E., Lee A.M., et al. Reference ranges for cardiac structure and&#xa0;function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. J.&#xa0;Cardiovasc. Magn. Reson. 2017;19:18. doi: 10.1186/s12968-017-0327-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12968-017-0327-9</ArticleId><ArticleId IdType="pmc">PMC5304550</ArticleId><ArticleId IdType="pubmed">28178995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestroni L., Maisch B., McKenna W.J., Schwartz K., Charron P., Rocco C., Tesson F., Richter A., Wilke A., Komajda M. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur. Heart J. 1999;20:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">10099905</ArticleId></ArticleIdList></Reference><Reference><Citation>McNally E.M., Mestroni L. Dilated cardiomyopathy: Genetic determinants and mechanisms. Circ. Res. 2017;121:731&#x2013;748. doi: 10.1161/CIRCRESAHA.116.309396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.309396</ArticleId><ArticleId IdType="pmc">PMC5626020</ArticleId><ArticleId IdType="pubmed">28912180</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Malley K.J., Cook K.F., Price M.D., Wildes K.R., Hurdle J.F., Ashton C.M. Measuring diagnoses: ICD code accuracy. Health Serv. Res. 2005;40:1620&#x2013;1639. doi: 10.1111/j.1475-6773.2005.00444.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1475-6773.2005.00444.x</ArticleId><ArticleId IdType="pmc">PMC1361216</ArticleId><ArticleId IdType="pubmed">16178999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershberger R.E., Hedges D.J., Morales A. Dilated cardiomyopathy: The complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 2013;10:531&#x2013;547. doi: 10.1038/nrcardio.2013.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2013.105</ArticleId><ArticleId IdType="pubmed">23900355</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah R., Asatryan B., Dabbagh G.S., Khanji M., van Duijvenboden S., Muser D., Landstrom A.P., Semsarian C., Somers V., Munroe P.B., Chahal A.A. Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK Biobank Participants. Circulation. 2022;19:101&#x2013;102. doi: 10.1161/CIRCULATIONAHA.121.058143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.058143</ArticleId><ArticleId IdType="pmc">PMC9375305</ArticleId><ArticleId IdType="pubmed">35708014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindeboom R.G.H., Supek F., Lehner B. The rules&#xa0;and impact of nonsense-mediated mRNA decay in human cancers. Nat. Genet. 2016;48:1112&#x2013;1118. doi: 10.1038/ng.3664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3664</ArticleId><ArticleId IdType="pmc">PMC5045715</ArticleId><ArticleId IdType="pubmed">27618451</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggerty C.M., Damrauer S.M., Levin M.G., Birtwell D., Carey D.J., Golden A.M., Hartzel D.N., Hu Y., Judy R., Kelly M.A., et al. Genomics-First Evaluation of Heart Disease&#xa0;Associated With Titin-Truncating Variants. Circulation. 2019;140:42&#x2013;54. doi: 10.1161/CIRCULATIONAHA.119.039573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.039573</ArticleId><ArticleId IdType="pmc">PMC6602806</ArticleId><ArticleId IdType="pubmed">31216868</ArticleId></ArticleIdList></Reference><Reference><Citation>Saltzman A.J., Mancini-DiNardo D., Li C., Chung W.K., Ho C.Y., Hurst S., Wynn J., Care M., Hamilton R.M., Seidman G.W., et al. Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy. Circ. Res. 2010;106:1549&#x2013;1552. doi: 10.1161/CIRCRESAHA.109.216291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.109.216291</ArticleId><ArticleId IdType="pmc">PMC2893345</ArticleId><ArticleId IdType="pubmed">20378854</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiffin N., Minikel E., Walsh R., O&#x2019;Donnell-Luria A.H., Karczewski K., Ing A.Y., Barton P.J.R., Funke B., Cook S.A., Macarthur D., Ware J.S. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet. Med. 2017;19:1151&#x2013;1158. doi: 10.1038/gim.2017.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2017.26</ArticleId><ArticleId IdType="pmc">PMC5563454</ArticleId><ArticleId IdType="pubmed">28518168</ArticleId></ArticleIdList></Reference><Reference><Citation>Fry A., Littlejohns T.J., Sudlow C., Doherty N., Adamska L., Sprosen T., Collins R., Allen N.E. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am. J. Epidemiol. 2017;186:1026&#x2013;1034. doi: 10.1093/aje/kwx246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwx246</ArticleId><ArticleId IdType="pmc">PMC5860371</ArticleId><ArticleId IdType="pubmed">28641372</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>McAfee Q., Chen C.Y., Yang Y., Caporizzo M.A., Morley M., Babu A., Jeong S., Brandimarto J., Bedi K.C., Flam E., et al. Truncated titin proteins in dilated cardiomyopathy. Sci. Transl. Med. 2021;13 doi: 10.1126/scitranslmed.abd7287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd7287</ArticleId><ArticleId IdType="pmc">PMC9236909</ArticleId><ArticleId IdType="pubmed">34731015</ArticleId></ArticleIdList></Reference><Reference><Citation>Fomin A., G&#xe4;rtner A., Cyganek L., Tiburcy M., Tuleta I., Wellers L., Folsche L., Hobbach A.J., von Frieling-Salewsky M., Unger A., et al. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations. Sci. Transl. Med. 2021;13 doi: 10.1126/scitranslmed.abd3079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3079</ArticleId><ArticleId IdType="pubmed">34731013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>